Abstract

The acceleration of drug efflux activity realized by plasma membrane transporters in neoplastic cells, particularly by P-glycoprotein (P-gp, ABCB1 member of the ABC transporter family), represents a frequently observed molecular cause of multidrug resistance (MDR). This multiple resistance represents a real obstacle in the effective chemotherapy of neoplastic diseases. Therefore, identifying cytotoxic substances that are also effective in P-gp overexpressing cells may be useful for the rational design of substances for the treatment of malignancies with developed MDR. Here, we showed that triorganotin derivatives—tributyltin-chloride (TBT-Cl), tributyltin-bromide (TBT-Br), tributyltin-iodide (TBT-I) and tributyltin-isothiocyanate (TBT-NCS) or triphenyltin-chloride (TPT-Cl) and triphenyltin-isothiocyanate (TPT-NCS)—could induce the death of L1210 mice leukemia cells at a submicromolar concentration independently of P-gp overexpression. The median lethal concentration obtained for triorganotin derivatives did not exceed 0.5 µM in the induction of cell death of either P-gp negative or P-gp positive L1210 cells. Apoptosis related to regulatory pathway of Bcl-2 family proteins seems to be the predominant mode of cell death in either P-gp negative or P-gp positive L1210 cells. TBT-Cl and TBT-Br were more efficient with L1210 cells overexpressing P-gp than with their counterpart P-gp negative cells. In contrast, TBT-I and TPT-NCS induced a more pronounced cell death effect on P-gp negative cells than on P-gp positive cells. Triorganotin derivatives did not affect P-gp efflux in native cells measured by calcein retention within the cells. Taken together, we assumed that triorganotin derivatives represent substances suitable for suppressing the viability of P-gp positive malignant cells.

Highlights

  • Important progress in the development of modern protocols for the targeted therapy of cancer was achieved during the past decade [1]

  • We further examined the mode of cell death induced by triorganotin derivatives

  • Triorganotin derivatives induced a cell death effect on all variants of L1210 cells applied in the present study at submicromolar levels

Read more

Summary

Introduction

Important progress in the development of modern protocols for the targeted therapy of cancer was achieved during the past decade [1]. The targeting of neoplastic cells with small molecules that could induce the elimination of neoplastic cells with a specific phenotype represents an important issue for biomedical research [2]. Even if the impressive responses of these therapies were fulfilled, several individuals are non-responders and show signs of drug resistance that may occur due to the phenotypic plasticity of cancer cells [3]. Malignant cells could develop resistance to a wide group of structurally unrelated substances with different mechanisms of anticancer action—multidrug resistance (MDR) [5]. A typical feature of P-gp represents broad substrate specificity to large but well-defined groups of structurally unrelated chemicals belonging to a cluster of P-gp substrates. When expressed in neoplastic cells, P-gp could cause massive drug resistance to its substrates involving anthracyclines (e.g., doxorubicin), Vinca alkaloids

Methods
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call